Our data on HER3 upregulation are in line with previous results in trastuzumab-resistant HER2-overexpressing BT-474 breast carcinoma cells generated in vivo that showed higher levels of phosphorylated HER3 [45]. Here, ERBB2 is linked to breast carcinoma.